Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls

By /

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.

Scroll to Top